ABBOTT LABORATORIES (NYSE:ABT) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial
Condition
On April19, 2017, Abbott Laboratories announced its results of
operations for the first quarter 2017.
Furnished as Exhibit99.1, and incorporated herein by reference,
is the news release issued by Abbott announcing those results. In
that news release, Abbott uses various non-GAAP financial
measures including, among others, net earnings from continuing
operations excluding specified items. These non-GAAP financial
measures adjust for factors that are unusual or unpredictable,
such as expenses primarily associated with acquisitions,
restructuring actions, and cost reduction initiatives, a gain on
the sale of the Medical Optics business, foreign exchange loss
related to Venezuela, and resolution of various tax positions
from prior years. These non-GAAP financial measures also exclude
intangible amortization expense to provide greater visibility on
the results of operations excluding these costs, similar to how
Abbotts management internally assesses performance. Abbotts
management believes the presentation of these non-GAAP financial
measures provides useful information to investors regarding
Abbotts results of operations as these non-GAAP financial
measures allow investors to better evaluate ongoing business
performance. Abbotts management also uses these non-GAAP
financial measures internally to monitor performance of the
businesses. Abbott, however, cautions investors to consider these
non-GAAP financial measures in addition to, and not as a
substitute for, financial measures prepared in accordance with
GAAP.
Item 9.01 Financial Statements and
Exhibits
|
ExhibitNo. |
|
Exhibit |
|
99.1 |
Press Release dated April19, 2017 (furnished to Item 2.02). |
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
ABBOTT LABORATORIES |
||
|
Date: April19, 2017 |
By: |
/s/ Brian B. Yoor |
|
Brian B. Yoor |
||
|
Executive Vice President, Finance and Chief Financial |
EXHIBITINDEX
|
ExhibitNo. |
|
Exhibit |
|
99.1 |
Press Release dated April19, 2017 (furnished |
About ABBOTT LABORATORIES (NYSE:ABT)
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Nutrition Products segment includes the sales of a line of adult and pediatric nutritional products. The Diagnostic Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products. ABBOTT LABORATORIES (NYSE:ABT) Recent Trading Information
ABBOTT LABORATORIES (NYSE:ABT) closed its last trading session up +0.10 at 43.43 with 10,131,161 shares trading hands.